• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: ''Risk and benefit of mRNA COVID-19 vaccines for the omicron variant by age, sex, and presence of comorbidity: a quality-adjusted life years analysis''.

作者信息

Lataster Raphael

机构信息

Centre for Continuing Education, University of Sydney, Sydney, NSW 2042, Australia.

出版信息

Am J Epidemiol. 2024 Jun 3;193(6):928-929. doi: 10.1093/aje/kwad242.

DOI:10.1093/aje/kwad242
PMID:38100362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11145902/
Abstract
摘要

相似文献

1
Re: ''Risk and benefit of mRNA COVID-19 vaccines for the omicron variant by age, sex, and presence of comorbidity: a quality-adjusted life years analysis''.关于：“按年龄、性别和合并症情况分析mRNA新冠疫苗对奥密克戎变异株的风险与益处：质量调整生命年分析”
Am J Epidemiol. 2024 Jun 3;193(6):928-929. doi: 10.1093/aje/kwad242.
2
Re: "Risk and benefit of mRNA COVID-19 vaccines for the omicron variant by age, sex, and presence of comorbidity: a quality-adjusted life years analysis".关于：“按年龄、性别和合并症情况分析mRNA新冠疫苗对奥密克戎变异株的风险与获益：质量调整生命年分析”
Am J Epidemiol. 2024 Jun 3;193(6):930-931. doi: 10.1093/aje/kwad238.
3
RE: "RISK AND BENEFIT OF mRNA COVID-19 VACCINES FOR THE OMICRON VARIANT BY AGE, SEX, AND PRESENCE OF COMORBIDITY: A QUALITY-ADJUSTED LIFE YEARS ANALYSIS".主题：“按年龄、性别和合并症情况分析mRNA新冠疫苗对奥密克戎变异株的风险与益处：质量调整生命年分析”
Am J Epidemiol. 2023 Jun 2;192(6):1031. doi: 10.1093/aje/kwad069.
4
Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis.奥密克戎变异株流行期间，mRNA COVID-19 疫苗接种的风险与获益：基于质量调整生命年的分析。
Am J Epidemiol. 2023 Jul 7;192(7):1137-1147. doi: 10.1093/aje/kwad058.
5
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
6
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
7
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
8
Willingness to Wait for a Vaccine Against COVID-19: Results of a Preference Survey.等待新冠疫苗的意愿：一项偏好调查结果
Patient. 2021 May;14(3):373-377. doi: 10.1007/s40271-020-00483-y. Epub 2020 Dec 14.
9
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.疫苗对 Alpha、Delta 或奥密克戎变异株流行期间 SARS-CoV-2 再感染的有效性：一项丹麦全国性研究。
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.
10
Benefit-Risk Assessment of mRNA COVID-19 Vaccines in Children Aged 6 Months to 4 Years in the Omicron Era.奥密克戎时代 6 月龄至 4 岁儿童接种 mRNA COVID-19 疫苗的获益-风险评估。
J Pediatric Infect Dis Soc. 2024 Feb 26;13(2):129-135. doi: 10.1093/jpids/piae002.

本文引用的文献

1
Reply to Fung et al. on COVID-19 vaccine case-counting window biases overstating vaccine effectiveness.对冯等人关于新冠疫苗病例计数窗口偏差夸大疫苗有效性的回复。
J Eval Clin Pract. 2024 Feb;30(1):82-85. doi: 10.1111/jep.13892. Epub 2023 Jul 4.
2
Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.2019年冠状病毒病二价疫苗的有效性。
Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209. eCollection 2023 Jun.
3
COVID-19 vaccination-related myocarditis: a Korean nationwide study.COVID-19 疫苗相关心肌炎：一项韩国全国性研究。
Eur Heart J. 2023 Jun 25;44(24):2234-2243. doi: 10.1093/eurheartj/ehad339.
4
Sources of bias in observational studies of covid-19 vaccine effectiveness.新冠病毒 19 疫苗有效性观察性研究中的偏倚来源。
J Eval Clin Pract. 2024 Feb;30(1):30-36. doi: 10.1111/jep.13839. Epub 2023 Mar 26.
5
Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis.奥密克戎变异株流行期间，mRNA COVID-19 疫苗接种的风险与获益：基于质量调整生命年的分析。
Am J Epidemiol. 2023 Jul 7;192(7):1137-1147. doi: 10.1093/aje/kwad058.
6
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.与 SARS-CoV-2 感染和卡塔尔严重 COVID-19 相比，先前自然感染的保护作用：一项回顾性队列研究。
Lancet Microbe. 2022 Dec;3(12):e944-e955. doi: 10.1016/S2666-5247(22)00287-7. Epub 2022 Nov 11.
7
Autopsy findings of post-COVID-19 vaccination deaths in Tokyo Metropolis, Japan, 2021.日本东京都 2021 年 COVID-19 疫苗接种后死亡的尸检结果。
Leg Med (Tokyo). 2022 Nov;59:102134. doi: 10.1016/j.legalmed.2022.102134. Epub 2022 Aug 20.
8
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.保护和衰减对 SARS-CoV-2 的天然和混合免疫。
N Engl J Med. 2022 Jun 9;386(23):2201-2212. doi: 10.1056/NEJMoa2118946. Epub 2022 May 25.